HuidaGene Therapeutics Co., Ltd.

7 clinical trials · Sponsor

Record	Firm	Date
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease (NCT07063251)	HuidaGene Therapeutics Co., Ltd.	2025-08-20
Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial (NCT06623279)	HuidaGene Therapeutics Co., Ltd.	2025-04-01
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO) (NCT06615206)	HuidaGene Therapeutics Co., Ltd.	2024-10-30
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) (NCT05906953)	HuidaGene Therapeutics Co., Ltd.	2023-10-31
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) (NCT06031727)	HuidaGene Therapeutics Co., Ltd.	2023-09-04
a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND) (NCT06025032)	HuidaGene Therapeutics Co., Ltd.	2023-03-30

Every clearance here is in the API, with alerts when new ones post.